Bonn
Bonn
Bonn, Bonn, Germany3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-08-03 | NCT07019922 | |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, acquired idiopathic inflammatory myopathy, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, scleroderma, skin disorder, systemic sclerosis | Recruiting | Phase 2 | 2026-07-31 | NCT06991114 | |
| Pazopanib Vs. Pazopanib Plus Gemcitabine | Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, carcinosarcoma, leiomyosarcoma, mixed neoplasm, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2024-11-15 | NCT02203760 |